Barinthus Biotherapeutics (BRNS) Change in Cash (2020 - 2026)
Barinthus Biotherapeutics' (BRNS) quarterly Change in Cash came in at -$4.7 million in Q1 2026, up 60.55% YoY from -$2.9 million in Q1 2025, and down 22.0% on a QoQ basis from -$3.8 million in Q4 2025.
Barinthus Biotherapeutics (BRNS) Change in Cash (2020 - 2026) Analysis & Trends
Barinthus Biotherapeutics (BRNS) has 7 years of Change in Cash data on file, last reported at -$4.7 million in Q1 2026.
- Quarterly Change in Cash rose 60.55% year-over-year to -$4.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$33.4 million (down 13.6% YoY) and the FY2025 annual result came in at -$40.5 million, down 36.57% from the prior year.
- Change in Cash eased to -$4.7 million in Q1 2026, from -$3.8 million in the prior quarter.
- In the past five years, Change in Cash ranged from a high of $7.8 million in Q3 2022 to a low of -$18.3 million in Q2 2023.
- A 5-year average of -$8.6 million and a median of -$11.8 million in 2025 frame the typical range for Change in Cash.
- Annual changes were most pronounced in 2022 — Change in Cash soared 179.78% — and 2024, when it slumped 296.43%.
- Tracing BRNS's Change in Cash over 5 years: stood at -$5.7 million in 2022, then tumbled by 218.57% to -$18.2 million in 2023, then jumped by 134.57% to $6.3 million in 2024, then sank by 160.69% to -$3.8 million in 2025, then declined by 22.0% to -$4.7 million in 2026.
- The last three Change in Cash figures came in at -$4.7 million (Q1 2026), -$3.8 million (Q4 2025), and -$12.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Cash (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 649.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -504.60 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -185.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 427.25 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -2.94 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -37.42 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 225.59 Mn |
| 10 | Barinthus Biotherapeutics | 25.40 Mn | 25.40 Mn | - | -7.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -7.56 Mn |
| Mar 31, 2026 | -4.66 Mn |
| Dec 31, 2025 | -3.82 Mn |
| Sep 30, 2025 | -12.11 Mn |
| Jun 30, 2025 | -12.80 Mn |
| Mar 31, 2025 | -11.82 Mn |
| Dec 31, 2024 | 6.30 Mn |
| Sep 30, 2024 | -11.67 Mn |
| Jun 30, 2024 | -12.20 Mn |
| Mar 31, 2024 | -12.12 Mn |
| Dec 31, 2023 | -18.22 Mn |
| Sep 30, 2023 | -12.72 Mn |
| Jun 30, 2023 | -18.30 Mn |
| Mar 31, 2023 | -3.06 Mn |
| Dec 31, 2022 | -5.72 Mn |
| Sep 30, 2022 | 7.78 Mn |
| Jun 30, 2022 | -8.27 Mn |
| Mar 31, 2022 | -13.46 Mn |
| Dec 31, 2021 | -19.82 Mn |
| Sep 30, 2021 | -9.75 Mn |